Sagimet Biosciences Completes End-of-Phase 2 Interactions With FDA On Development Of Denifanstat For MASH, Says Expects Phase 3 Program Initiation By End Of 2024
Portfolio Pulse from Benzinga Newsdesk
Sagimet Biosciences has completed end-of-Phase 2 interactions with the FDA regarding the development of Denifanstat for MASH. The company anticipates initiating the Phase 3 program by the end of 2024.
October 29, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sagimet Biosciences has successfully completed end-of-Phase 2 interactions with the FDA for Denifanstat, a treatment for MASH. The company plans to start Phase 3 trials by the end of 2024.
The completion of end-of-Phase 2 interactions with the FDA is a significant milestone for Sagimet Biosciences, indicating progress in the development of Denifanstat for MASH. The anticipation of Phase 3 trials by the end of 2024 suggests a positive outlook for the company's future developments, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100